Monopar Therapeutics (MNPR)
117.56
-0.99 (0.84%)
Upcoming Events
Latest Headlines
Form 4/A Monopar Therapeutics For: Aug 26 Filed by: Tsuchimoto Kim R
August 28, 2026 8:18 PM - SEC Filing
Form 4/A Monopar Therapeutics For: Aug 25 Filed by: Anderson Raymond
August 28, 2026 7:41 PM - SEC Filing
Form 4 Monopar Therapeutics For: Aug 26 Filed by: RIOUX PATRICE
August 27, 2026 7:29 PM - SEC Filing
Form 4 Monopar Therapeutics For: Aug 26 Filed by: Tsuchimoto Kim R
August 27, 2026 6:29 PM - SEC Filing
Form 4 Monopar Therapeutics For: Aug 25 Filed by: Anderson Raymond
August 27, 2026 6:28 PM - SEC Filing
Form 144 Monopar Therapeutics Filed by: RIOUX PATRICE
August 26, 2026 4:20 PM - SEC Filing
Form 144 Monopar Therapeutics Filed by: Tsuchimoto Kim R
August 26, 2026 4:18 PM - SEC Filing
Form 144 Monopar Therapeutics Filed by: Anderson Raymond
August 25, 2026 4:45 PM - SEC Filing
Monopar names medical affairs chief, gets two AASLD presentations
August 19, 2026 8:00 AM - StreetInsider
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
August 19, 2026 8:00 AM - StreetInsider
Monopar Therapeutics (MNPR) PT Raised to $130 at Morgan Stanley
August 17, 2026 8:58 AM - StreetInsider
Monopar Therapeutics (MNPR) PT Raised to $128 at Barclays
August 13, 2026 5:38 AM - StreetInsider
Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral
August 13, 2026 4:24 AM - StreetInsider
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: Saturn V Capital Management LP
August 12, 2026 6:26 PM - SEC Filing
Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
August 12, 2026 3:48 PM - StreetInsider
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: Adage Capital Management, L.P.
August 12, 2026 12:05 PM - SEC Filing
Form 8-K Monopar Therapeutics For: Aug 12
August 12, 2026 9:31 AM - SEC Filing
Form 10-Q Monopar Therapeutics For: Jun 30
August 12, 2026 9:31 AM - SEC Filing
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 12, 2026 9:30 AM - StreetInsider
Monopar Therapeutics (MNPR) PT Raised to $125 at H.C. Wainwright
July 23, 2026 7:12 AM - StreetInsider
Form S-8 POS Monopar Therapeutics
July 22, 2026 4:17 PM - SEC Filing
Form S-8 POS Monopar Therapeutics
July 22, 2026 4:17 PM - SEC Filing
Form S-8 POS Monopar Therapeutics
July 22, 2026 4:17 PM - SEC Filing
Form S-8 Monopar Therapeutics
July 22, 2026 4:16 PM - SEC Filing
Form S-8 POS Monopar Therapeutics
July 22, 2026 4:16 PM - SEC Filing
Monopar begins rolling NDA submission for Wilson disease drug
July 22, 2026 8:02 AM - StreetInsider
Form 8-K Monopar Therapeutics For: Jul 22
July 22, 2026 8:00 AM - SEC Filing
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
July 22, 2026 8:00 AM - StreetInsider
Monopar adds commercial leaders ahead of potential ALXN1840 launch
July 20, 2026 8:00 AM - StreetInsider
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
July 20, 2026 8:00 AM - StreetInsider
Monopar Therapeutics (MNPR) Reiterated at Overweight by Cantor Fitzgerald
July 15, 2026 7:45 AM - StreetInsider
Form 144/A Monopar Therapeutics Filed by: KLAUSNER ARTHUR J
July 10, 2026 6:02 PM - SEC Filing
Form 144 Monopar Therapeutics Filed by: KLAUSNER ARTHUR J
July 7, 2026 2:29 PM - SEC Filing
Form 4 Monopar Therapeutics For: Jun 30 Filed by: Vu Quan Anh
July 2, 2026 7:38 PM - SEC Filing
Form 4 Monopar Therapeutics For: Jun 30 Filed by: Robinson Chandler
July 2, 2026 7:38 PM - SEC Filing
Form 4 Monopar Therapeutics For: Jun 30 Filed by: Cittadine Andrew
July 2, 2026 7:38 PM - SEC Filing
Form 4 Monopar Therapeutics For: Jun 26 Filed by: Sweeny Nicole
June 30, 2026 4:58 PM - SEC Filing
Form 3 Monopar Therapeutics For: Jun 22 Filed by: Sweeny Nicole
June 30, 2026 4:57 PM - SEC Filing
Form 8-K Monopar Therapeutics For: Jun 30
June 30, 2026 8:00 AM - SEC Filing
Monopar wins FDA rare pediatric disease tag for Wilson disease drug
June 30, 2026 8:00 AM - StreetInsider
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
June 30, 2026 8:00 AM - StreetInsider
Monopar Therapeutics (MNPR) PT Raised to $117 at BTIG
June 30, 2026 6:04 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR)
June 29, 2026 7:08 AM - StreetInsider
Form 8-K Monopar Therapeutics For: Jun 26
June 26, 2026 4:06 PM - SEC Filing
Monopar presents Phase 3 Wilson disease data at EAN 2026
June 26, 2026 4:05 PM - StreetInsider
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
June 26, 2026 4:05 PM - StreetInsider
Form 8-K Monopar Therapeutics For: Jun 22
June 23, 2026 8:01 AM - SEC Filing
Full Article List
